Abstract
Research into the PD-1 pathway has been shown to be valuable in the immune system’s ability to control cancer. Blocking this pathway with targeted therapies such as nivolumab has led to tumor response and control in some patients with non–small cell lung cancer. Learn about this recently approved agent, including the most important facts necessary for successful management of patients on this therapy.
